Good news: Merck to add 310 jobs; bad news: Biovail/Valeant to cut 1,100

It promised North Carolina 440 jobs in two years to meet increased demand for its vaccines. Merck now says it will add 310 more. "We have grown much faster than anyone had anticipated," says plant manager John Wagner. Separately, the drug giant says it is delaying the closure of some Dutch operations while it sorts out alternatives for employees.  Both the U.S. and Canada will suffer job losses thanks to synergies identified in the Biovail acquisition of Valeant. The combined 4,400-employee workforce is expected to be trimmed by 25 percent. Report | Article | Article

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.